Piramal Enterprises is reportedly looking to expand its footprint in its pharma vertical in global markets such as the US, Europe and Japan. In this regards, the company is planning to introduce more products.
The company will continue to add more generic hospital products both organically and inorganically to leverage its strong sales and distribution network, integrating acquired products and generating synergies.
The company generates over 70% of its revenue from pharmaceuticals business in North America and Europe. Its pharma vertical is divided into two - the global pharma business that sells pharma products and services globally and the India consumer products business that sells OTC products in India.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 955.05 |
| Shriram Finance | 1007.95 |
| Aditya Birla Capital | 363.05 |
| Chola Invest & Fin. | 1676.05 |
| Tata Capital | 321.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: